The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA
Remidex manufactures micronutrient premixes and nutraceuticals,
This inspection is now closed
The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
Launches advanced bone density systems in India & Dubai
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Subscribe To Our Newsletter & Stay Updated
